B · Normal
[Baili Tianheng: Renkang Ilontumab for Injection is included in the National Medical Insurance Catalog] On November 15th, Bailey Tianheng (688506.SH) announced that the world's first dual-antibody ADC drug Renkang Ilontumab for injection, independently developed by the company's wholly-owned subsidiary, passed the national medical insurance negotiations in the first year of its launch. Successfully included in the "National Medical Insurance Catalog (2026 Edition)", the agreement is valid from January 1, 2027 to December 31, 2028. The payment scope is limited to adult patients with recurrent/metastatic nasopharyngeal cancer who have received at least second-line systemic chemotherapy and failed PD-1/PD-L1 inhibitor treatment.
A-share announcement express 🕐 2026-11-15 16:29

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet